Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the current ratio high or low?
The current ratio of 50.82 is 499% above its 5-year average of 8.49, near the high end of its 5-year range (4.75–50.82).
As of the fiscal period ended Tuesday, June 30, 2026. 134.97% above its 12-month average of 21.63.
Reported quarterly current ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 50.82.
CURRENT RATIO
50.82
CURRENT RATIO AVG TTM
21.63
CURRENT RATIO AVG 3Y
7.27
CURRENT RATIO AVG 5Y
8.49
CURRENT RATIO AVG 10Y
N/A
CURRENT RATIO AVG 15Y
N/A
CURRENT RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
+134.97%
CURRENT VS 3Y AVG
+599.57%
CURRENT VS 5Y AVG
+498.76%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
3.75
median of 874 covered companies
CURRENT VS SECTOR MEDIAN
+1255.30%
vs the sector median at left
Tango Therapeutics, Inc.
Market Cap
$3.57B
Current Ratio
50.82
TTM Avg
21.63
3Y Avg
7.27
5Y Avg
8.49
Market Cap
$3.53B
Current Ratio
3.87
TTM Avg
5.22
3Y Avg
3.96
5Y Avg
4.18
Market Cap
$3.52B
Current Ratio
21.02
TTM Avg
15.64
3Y Avg
20.34
5Y Avg
22.11
Market Cap
$3.65B
Current Ratio
1.42
TTM Avg
24.66
3Y Avg
24.23
5Y Avg
16.18
Market Cap
$3.46B
Current Ratio
10.45
TTM Avg
13.16
3Y Avg
14.41
5Y Avg
11.78
Market Cap
$3.38B
Current Ratio
3.39
TTM Avg
3.10
3Y Avg
3.17
5Y Avg
4.31
| NAME | MARKET CAP | CURRENT RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Tango Therapeutics, Inc. (TNGX) | $3.57B | 50.82 | 21.63 | 7.27 | 8.49 |
| Veracyte, Inc. (VCYT)vs › | $3.55B | 9.16 | 6.44 | 5.38 | 7.95 |
| iRhythm Technologies, Inc. (IRTC)vs › | $3.53B | 3.87 | 5.22 | 3.96 | 4.18 |
| Xenon Pharmaceuticals Inc. (XENE)vs › | $3.52B | 21.02 | 15.64 | 20.34 | 22.11 |
| Regencell Bioscience Holdings Limited (RGC)vs › | $3.65B | 1.42 | 24.66 | 24.23 | 16.18 |
| Celcuity Inc. (CELC)vs › | $3.47B | 8.93 | 9.13 | 14.29 | 16.91 |
| IDEAYA Biosciences, Inc. (IDYA)vs › | $3.46B | 10.45 | 13.16 | 14.41 | 11.78 |
| Pulse Biosciences, Inc. (PLSE)vs › | $3.43B | 9.63 | 11.21 | 9.89 | 7.80 |
| Acadia Pharmaceuticals Inc. (ACAD)vs › | $3.38B | 3.39 | 3.10 | 3.17 | 4.31 |
| Parabilis Medicines, Inc. (PBLS)vs › | $3.37B | 17.91 | 1.68 | 1.68 | 1.68 |
Current Ratio
50.82
Quick Ratio
50.82
Current Ratio = Current Assets / Current Liabilities
The current ratio measures short-term liquidity — a company's ability to cover current liabilities with current assets. Above 1.0 indicates positive working capital.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | CURRENT RATIO |
|---|---|
| 2026-06-30 | 50.82 |
| 2026-03-31 | 27.38 |
| 2025-12-31 | 16.32 |
| 2025-09-30 | 8.88 |
| 2025-06-30 | 4.75 |
| 2025-03-31 | 6.26 |
| 2024-12-31 | 6.98 |
| 2024-09-30 | 8.00 |
| 2024-06-30 | 7.49 |
| 2024-03-31 | 8.23 |
| 2023-12-31 | 7.54 |
| 2023-09-30 | 8.54 |
| 2023-06-30 | 5.98 |
| 2023-03-31 | 6.39 |
| 2022-12-31 | 6.76 |
| 2022-09-30 | 7.83 |
| 2022-06-30 | 9.76 |
| 2022-03-31 | 11.75 |
| 2021-12-31 | 12.10 |
| 2021-09-30 | 12.30 |
| 2021-06-30 | 5.43 |
| 2021-03-31 | 5.71 |
| 2020-12-31 | 4.73 |
| 2020-09-30 | 14.10 |
| 2020-06-30 | 0.64 |
| 2020-03-31 | 0.00 |
